Raymond James Financial Services Advisors, Inc. Supernus Pharmaceuticals, Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2018 Nov 14, 2018	SELL	$42.7 - $56.55 $288,182 - $381,655	-6,749 Closed	0 $0
Q2 2018 Jul 30, 2018	BUY	$44.1 - $59.85 $297,630 - $403,927	6,749 New	6,749 $404,000

Others Institutions Holding SUPN

# of Institutions

282

Shares Held

60.9M

Call Options Held

27.7K

Put Options Held

11.3K

Black Rock Inc. New York, NY

10.4M
Shares

$382 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

6.13M
Shares

$225 Million
0.0% of portfolio
Armistice Capital, LLC New York, NY

5.1M
Shares

$187 Million
2.64% of portfolio
Dimensional Fund Advisors LP Austin, TX

2.88M
Shares

$106 Million
0.02% of portfolio
Macquarie Group LTD Australia, C3

2.63M
Shares

$96.7 Million
0.09% of portfolio

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.97B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account